

MÉDICA: 2Q21 Results

Outstanding Results, Once Again Above our Forecasts

BUY	
Target Price (MXN\$)	\$ 46.00
Current Price (MXN\$)	\$ 32.50
Min / Max (L12M)	\$15.00 - 38.70
Expected Dividend (MXN\$)	\$ 0.70
Expected Return	43.7%
Market Cap (MXN\$ Mn)	4,334
Enterprise Value (MXN\$ Mn)	4,410
Outstanding Shares (Mn)	133.4
Float	49.9%
ADTV (MXN\$ Mn)	\$ 0.73

Opinion and Recommendation

MÉDICA reported outstanding 2Q21 results driven by a significant recovery in hospital and non-COVID diagnostic services that have exceeded pre-pandemic levels, in addition to the prevailing health situation. This resulted in a 65.8% increase in revenues and a 120.3% EBITDA growth. The bottom line also benefitted from lower interest payments, rising 334.5%. As a result of the strong free cash flow generation, MÉDICA reduced its net debt by 92.0% to only MXN\$66.1 million with a net debt to EBITDA ratio of practically 0x.


After these results, we reiterate our BUY recommendation with a MXN\$46.0/share target price. We believe that the company's operating performance will remain strong in the coming quarters, subject to vaccination levels.

Revenues

MÉDICA reported 2Q21 revenues of MXN\$1,389.7 million (+ 7.8% above our projections), up 65.8% annually. By business segment, hospital services revenues advanced 98.1%, diagnostics' +52.0% and "others" +24.2%.

Sales levels were influenced by several factors such as the significant recovery in hospital and diagnostic services other than COVID, which have even exceeded pre-pandemic levels, mainly in surgical activity; the recovery of clinical services and diagnostic units such as the radiotherapy, neurophysiology, advanced urology and radiosurgery cancer center; and a higher number of hospitalized patients COVID-19, as well as a greater amount of tests related to such disease. Since the beginning of the pandemic, MÉDICA has treated more than 1,600 patients and has applied more than 700 thousand tests.

As a result, the company treated 3,158 hospitalization patients during the quarter, with a 62% increase. The average bill per patient was MXN\$166,493, up 22.2%.



July 19th, 2021

Martin Lara
 +5255-6413-8563
 martin.lara@miranda-gr.com

The average stay of Non-COVID patients rose slightly from 3.48 to 3.74 days. However, the average stay of non-critical COVID-19 patients decreased from 7.20 to 6.19 days, while that of critical COVID-19 patients fell from 16.81 days to 14.15 days.

Diagnostic units reached 124 thanks to the agreement with GAP, which also helped to expand coverage from 6 to 14 cities.

Profitability

EBITDA grew 120.3% YoY to MXN\$381.0 million (+ 11.5% against our estimate) thanks to the company's high operating leverage. The EBITDA margin expanded 6.8 percentage points to 27.4% (vs. 26.5% E).

Net profits advanced 334.5% YoY to MXN\$191.4 million (+ 13.8% vs. our projection) supported by lower interests paid on the Cebures MEDICA 20 compared to the interests paid on bank loans that the company previously had. Interest gains rose due to the higher cash position. This more than offset the FX and the increase in the fiscal reserve. The net margin expanded 8.5 percentage points to 13.8%.

Financial Structure

Interest-bearing liabilities were down 23.0% YoY to MXN\$1 billion, while the cash position was 96.5% YoY higher to MXN\$933.9 million. For this reason, net debt fell 92.0% to only MXN\$66.1 million, with a net debt to EBITDA ratio practically at 0x.









Others

- Last June, MÉDICA celebrated its 40th anniversary.
 - MEDICA is the sponsor of the Mexican Olympic Committee. It will apply 1,000 COVID-19 tests as a requirement for the arrival of Mexican athletes.
 - Laboratorio Médico Polanco is also an official sponsor of the #OlaParalímpica. It will conduct COVID-19 tests during the Mexican Athletics Open.
 - In April, the company renewed the magnetic resonance service incorporating the Magnetom Sola Siemens resonator with 1.5 Tesla Biomatrix technology.
 - MÉDICA rose 34 places in the ranking of Mexico's 500 largest companies according to the "Expansión" magazine.
-

(Figures in Millions of MXN\$)

INCOME STATEMENT	2Q21	2Q21E	Diff.	2Q20	Chg.
Revenues	1,390	1,290	7.8%	838	65.8%
Operating Profit	300	262	14.3%	90	233.5%
<i>Operating Margin</i>	<i>21.6%</i>	<i>20.3%</i>		<i>10.7%</i>	
EBITDA	381	342	11.5%	173	120.3%
<i>EBITDA Margin</i>	<i>27.4%</i>	<i>26.5%</i>		<i>20.6%</i>	
Financial Gains	3	6	-55.9%	5	-39.8%
Financial Cost	-27	-28	-3.1%	-38	-28.4%
Pre-Tax Profit	275	240	14.6%	56	388.0%
Income Tax & Profit Sharing	-84	-72	16.2%	-12	579.6%
<i>Tax & Profit Sharing Rate</i>	<i>30.4%</i>	<i>30.0%</i>		<i>21.9%</i>	
Profit Before Minorities	191	168	13.8%	44	334.5%
Minority Interest	-0	0	-308.1%	-0	216.7%
Net Profit	191	168	13.8%	44	334.5%
EPS	P\$ 1.43	P\$ 1.26	13.8%	P\$ 0.35	306.5%

(Figures in Millions of MXN\$)



Source: BMV

DISCLAIMER

The current report was prepared by Miranda Global Research ("Miranda GR") for Vector Casa de Bolsa, S.A. de C.V. The information is presented in summarized form and is not meant to be complete. There are no declarations or guarantees, expressed or implicit, in respect to the accuracy, impartiality or integrity of the information.

Miranda GR, in accordance to applicable legislation, has made sure that the presented personalized recommendation is reasonable to the client, as it has verified congruency between the client's profile and the profile of the financial product. Under no circumstance should it be understood that the fulfillment of the previously mentioned recommendation, guarantees the result or the success of the proposed strategies in the presented document.

The information included in this presentation was obtained from public and/or private sources. Projections or previsions included in this presentation, are a generalized recommendation and are based on subjective assumptions and estimations about events and circumstances that have not yet happened and are subjected to significant variations. Therefore, it is not possible to guarantee that any of the results included in the current report will happen in the future, in other words, it does not guarantee the result or the success of the posed strategies.

This report has been prepared solely with informational purposes. No declarations are made in respects to precision, sufficiency, veracity or accuracy of the information and opinions hereby included. Miranda GR will not answer (either because of negligence or for any other reason) for any damage or detriment derived or related to the use of this report or its content, or any connection to the report. Miranda GR is not responsible for the use or association with this report, including but not limited to, any declaration, expressed or implicit or guarantees or omissions included in this information.

This report is based on facts and/or events that have happened up to this date, consequently any future facts and/or events can impair the conclusions hereby expressed. Miranda GR does not assume any responsibility to update, review, rectify or invalidate this report based on any future occurrence.

The opinions related to this report eventually expressed by Miranda GR, should be considered only as suggestions/recommendations to better operate various topics related to the presentation.

This report and its contents are property of Miranda GR and cannot be reproduced or broadcast in part or in its entirety without the previous written consent of Miranda GR.

Miranda Global Research receives fees from Médica Sur, S.A.B. de C.V. for independent analyst services.
